Related Experiment Video

Updated: Jul 19, 2026

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells
06:23

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells

Published on: November 21, 2025

Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway

G Wolf1

  • 1Klinik für Innere Medizin III, Klinikum der Friedrich-Schiller-Universität, Jena, Germany. Gunter.Wolf@med.uni-jena.de

Kidney International
|September 21, 2006
PubMed

Insights

The renin-angiotensin-aldosterone system (RAAS) activates transforming growth factor-beta (TGF-beta), a key driver of kidney fibrosis. Drugs targeting the RAAS may offer therapeutic potential for kidney disease.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Glomerulosclerosis, interstitial fibrosis, and tubular atrophy are hallmarks of end-stage kidney failure.
  • Transforming growth factor-beta (TGF-beta) is a critical mediator of kidney fibrosis, promoting extracellular matrix synthesis and fibroblast proliferation.
  • The renin-angiotensin-aldosterone system (RAAS) is increasingly recognized for its role in activating TGF-beta signaling in the kidney.

Purpose of the Study:

  • To review the intricate relationship between the RAAS and the TGF-beta signaling pathway in the context of kidney disease.
  • To highlight the mechanisms by which RAAS components stimulate TGF-beta expression and activity.
  • To discuss the therapeutic implications of targeting the RAAS to modulate TGF-beta-mediated kidney fibrosis.

Main Methods:

  • Literature review of studies investigating the RAAS and TGF-beta axis in kidney pathophysiology.
  • Analysis of experimental data demonstrating the effects of RAAS components on TGF-beta signaling.
  • Synthesis of current understanding regarding drug targets within the RAAS for kidney disease.

Main Results:

  • Angiotensin II (ANG II) directly and indirectly upregulates TGF-beta expression and its receptors in the kidney.
  • Other RAAS components, including ANG III, renin, and aldosterone, also activate the TGF-beta system.
  • ANG II can phosphorylate Smad proteins, a downstream signaling event in TGF-beta pathways, independent of TGF-beta induction.

Conclusions:

  • The RAAS plays a significant role in driving kidney fibrosis through TGF-beta activation.
  • Angiotensin-converting enzyme (ACE) inhibitors and angiotensin type 1 (AT1)-receptor blockers represent promising therapeutic strategies to interfere with ANG II-mediated TGF-beta signaling.
  • Further research into the RAAS-TGF-beta axis may unveil novel therapeutic targets for preventing and treating kidney fibrosis.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Related Concept Videos

Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...